세계의 내시경 역행 췌담관 조영술(ERCP) 시장 보고서 : 제품, 시술, 최종 사용자 및 지역별(2024-2032년)

The global endoscopic retrograde cholangiopancreatography market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.88% during 2024-2032.

Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.

Endoscopic Retrograde Cholangiopancreatography Market Trends:

The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett's disease, biliary, liver, Crohn's, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth. Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatography market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, procedure and end user.

Breakup by Product:

Endoscope

Endotherapy Devices

Sphincterotomes

Lithotripter

Stents

Others

Visualization Systems

Energy Devices

Others

Breakup by Procedure:

Biliary Sphincterotomy

Biliary Stenting

Biliary Dilatation

Pancreatic Sphincterotomy

Pancreatic Duct Stenting

Pancreatic Duct Dilatation

Breakup by End User:

Hospitals and Clinics

Ambulatory Surgery Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.

Key Questions Answered in This Report

• 1. How big is the global endoscopic retrograde cholangiopancreatography market?
• 2. What is the expected growth rate of the global endoscopic retrograde cholangiopancreatography market during 2024-2032?
• 3. What are the key factors driving the global endoscopic retrograde cholangiopancreatography market?
• 4. What has been the impact of COVID-19 on the global endoscopic retrograde cholangiopancreatography market?
• 5. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the product?
• 6. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the procedure?
• 7. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the end user?
• 8. What are the key regions in the global endoscopic retrograde cholangiopancreatography market?
• 9. Who are the key players/companies in the global endoscopic retrograde cholangiopancreatography market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Endoscopic Retrograde Cholangiopancreatography Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Endoscope
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Endotherapy Devices
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Sphincterotomes
    • 6.2.2.2 Lithotripter
    • 6.2.2.3 Stents
    • 6.2.2.4 Others
  • 6.2.3 Market Forecast
• 6.3 Visualization Systems
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Energy Devices
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Procedure

• 7.1 Biliary Sphincterotomy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Biliary Stenting
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Biliary Dilatation
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pancreatic Sphincterotomy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Pancreatic Duct Stenting
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Pancreatic Duct Dilatation
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgery Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Boston Scientific Corporation
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 CONMED Corporation
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Cook Group Incorporated
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Fujifilm Holdings Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Hobbs Medical Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Johnson & Johnson
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Medi-Globe GmbH
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Medtronic plc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Olympus Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Shaili Endoscopy
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Steris Corporation
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Telemed Systems Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio